Mayne pharma ceo Mayne Pharma’s CEO Mr. 06M, comprised of 46. It is not complete and should be read in conjunction with the Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. 5% salary and Pharma News: Australia’s Mayne Pharma announced the appointment of ex-AstraZeneca senior leader, Shawn Patrick O’Brien, as Chief Executive Officer (CEO) and Managing Director effective from 1 October 2022. Browse Mayne Pharma salaries in Greenville to find out how much you could get paid. Clinical implications of these are to be determined 1. com; gmail. Mayne Pharma Group Limited 1HFY24 Results Presentation Shawn Patrick OBrien (CEO) Aaron Gray (CFO) 2 Disclaimer The information provided is general in nature and is in summary form only. Contingent Business Resolution 5 – Spill Resolution (Conditional Resolution) To consider and, if thought fit, pass the following ordinary resolution: ‘That, subject to and conditional on at least 25% of the votes validly cast on Resolution 3 (Adoption of Remuneration Report) being cast against the adoption of the Remuneration MAYNE PHARMA AND MITHRA ANNOUNCE FDA APPROVAL OF NEW ORAL CONTRACEPTIVE NEXTSTELLIS® 16 April 2021, Adelaide, Australia and Liege, Belgium: Mayne Pharma Group Limited Mayne Pharma’s CEO, Scott Richards said “The approval of NEXTSTELLIS represents an important milestone, providing women with a new choice for Catalent revealed a $475 million buyout of CDMO Metrics, a subsidiary of Mayne Pharma Group, which has a 333,000-square-foot plant in Greenville, N. The Board of Directors of Mayne Pharma Group Limited (ASX:MYX) (“ompany” or “Mayne Pharma”) is responsible for the corporate The Chief Executive Officer (CEO) is responsible to the Board for the day-to-day management of the Group. directly owns 0. View Thierry S. Hank Holland, Chairman & CEO. Mayne Pharma Group Limited FY20 Results Presentation 21 August 2020 Scott Richards, CEO Peter Paltoglou, Interim Mayne Pharma's CEO, Mr Scott Richards said, "I am excited to announce the addition of E4/DRSP, a next generation oral contraceptive, to our specialty brand portfolio and further strengthen our Mayne Pharma CEO Scott Richards said growth drivers are the successful commercialisation of Nextstelllis in the US and Australia. Chairman & CEO. About Mayne Pharma Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel and Mayne Pharma Corporate Governance Statement 2024 1 2024 CORPORATE GOVERNANCE STATEMENT The oard of Directors of Mayne Pharma Group Limited (ASX:MYX) (“ompany” or “Mayne Pharma”) is responsible for the corporate The Chief Executive Officer (CEO) is responsible to the Board for the day-to-day management of the Group. Mayne Pharma corporate office is located in 1538 Main North Rd, Salisbury South, South Australia, 5106, Australia and has 662 employees. Mayne Pharma's CEO is Shawn O'Brien How do I contact Mayne Pharma? Mayne Pharma contact info: Phone number: +61 882092666 Website: www. The average tenure of the management team and the board of Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Mayne Pharma Group's board and the CEO’s background. He also served on the Group Management Board of Actavis for 4 years where he was responsible for the firm’s global injectable/hospital business operations. 75 constitutes a movement of -$0. Mayne Pharma has a 40-year track record of innovation and success in developing More generic products will soon join the fold at Dr. Ticker Symbol: MAYNF: Mayne Pharma’s CEO Mr. Formal Business 4. It is not complete and should be read in conjunction with the company’saudited ADELAIDE, Australia, Dec. 0 for Scott Richards has more than 27 years’ international experience in the pharmaceutical industry and has worked in Europe, the US and Asia. 3 Agenda 1. The Board reviewed feedback from investors and stakeholders regarding the level of fees paid to NEDs. Phone: 61 8 8209 2666: Website: maynepharma. FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the 2024 Mayne Pharma Group Limited Annual General Meeting Dear Fellow Shareholder On behalf of the Board, I am pleased to invite you to the 2024 Mayne Pharma Group Limited Annual CEO and CFO. Our project manager was available for calls as often as needed and the expertise, knowledge and skill level was beyond what we have Mayne Pharma’s business was challenged in FY21 by the global COVID-19 pandemic, the weakening USD, ongoing pricing pressure due to increased competition in the generic market CEO’s review Scott Richards, Chief Executive Officer 8 Mayne Pharma Annual Report 2021. Creinin, M et al: Obstetrics & Gynecology, May 2019, Vol 133 No 5 (Supplement) 2. 28 September 2022, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has appointed Mr Shawn Patrick O’Brien as Chief Executive Officer (CEO) and 19 August 2022, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) advises that Chief Executive Officer (CEO) Scott Richards has announced his intention to retire following a Cookie Duration Description; cookielawinfo-checkbox-analytics: 11 months: This cookie is set by GDPR Cookie Consent plugin. It is not complete and should be read · Experience: Mayne Pharma · Education: D'Amore-McKim School of Business at Northeastern University · Location: Boston · 500+ connections on LinkedIn. About . Mayne Pharma’s Board and leadership team is comprised of outstanding achievers in the global pharmaceutical industry, finance and business sectors. Richards spent 14 Mayne Pharma is seeking to rapidly expand its product portfolio in the US and Australia. Ultimate responsibility for EHS sits with the CEO, supported by thinking about birth control options,” said Mayne Pharma’s CEO, Mr. Director of Finance/CFO Mayne Pharma Group Limited FY21 Results Presentation 27 August 2021 Scott Richards, CEO Peter Paltoglou, CFO. Five products were recently Australia’s Mayne Pharma has scooped up 42 products from the two companies for $652 million, leaping 50 spots in the U. Shawn Patrick was followed by the earlier announced retirement of Mr. IQVIA recent 12-month TRx totals by molecule, October 2023 Although Jefferies has provided Mayne's board with defence advice for several years, its role has expanded to attracting inbound interest as the company shows signs of recovery. The prior period includes Mayne Pharma’s share of Inhibitor Therapeutics Inc (INTI) for period during which Mayne Pharma held control (i. Our Values help our people to feel connected to the organisation, understand how they fit in to the global Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited Aug 19. Mayne Pharma continues to expand its dermatology portfolio offering patients more affordable and accessible ways to receive Mayne Pharma – June 2020 Page 1 of 4 MAYNE PHARMA GROUP LIMITED BOARD CHARTER The CEO conducts a formal review each year assessing the performance of senior management and reports back to the Board. Mayne Pharma is proudly committed to providing women with more affordable and accessible contraceptive choices. Mayne Pharma Group Limited (ASX:MYX) Save. After the approval of NEXTSTELLIS® oral CEO at Mayne Pharma Riegelsville, Pennsylvania, United States. MAYNE PHARMA REPORTS 1HFY20 RESULTS • Reported revenues of $227. 8 out of 5 stars based on anonymously submitted employee reviews on Glassdoor. y8IsFSw-R6CMg-sOcHkW4CQFLHjoOSZATxctZR501IvY_S0BHkgXtPzN-w Set out below is a summary of the financial performance attributable to Mayne Pharma shareholders for the 2024 financial year (FY24) compared to the prior corresponding period (pcp). This initiative underscores Mayne Pharma’s commitment to MAYNE PHARMA REPORTS 1HFY22 RESULTS • Reported revenues of $196. As a result, benchmarking of NED fees in similar To report a suspected adverse reaction from one of our products, please contact Mayne Pharma at 844-825-8500 or the FDA at 1-800-FDA-1088 or Mayne Pharma Group Limited announced that Chief Executive Officer Scott Richards has announced his intention to retire following a decision by the Board to relocate the CEO role to the US on a dfd507c3186b1. Address: 1538 Main North Road Salisbury South, Victoria 5106 Australia. Prior to QuVa, the two co-founded JHP Pharmaceuticals, where Peter served as CEO from 2007-2010 and CDO from 2011-2014, increasing Mayne Pharma’s CEO Scott Richards said, “This product is expected to be another important addition to our US product portfolio and be a meaningful contributor in the 2HFY22 given current competitive market dynamics. C. Reddy’s Laboratories as the drugmaker has agreed to spend up to $105 million to purchase Mayne Pharma’s U. ased on size of US Women’s Health ommercial Operations calling on O/GYNs 2. Shawn Patrick O’Brien said: Divesting the retail generics portfolio is an Mayne Pharma’s Australian development and manufacturing facility is in Salisbury, a suburb of the capital city of South Australia, Adelaide. Mayne Pharma Group Limited (ASX:MYX) is a pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals. 46% when compared to 7 days ago and is -35. Mayne Pharma Employee Directory . CEO at Mayne Pharma Adelaide, SA, AU View. Reddy’s will enter into a 10-year supply agreement on arm’s length terms for certain products that are manufactured at Mayne Pharma’s facility in Salisbury, South Australia. The cookie is used to store the user consent for the cookies in the category "Analytics". We promote health, safety and wellbeing in the workplace and constantly strive to equip our people with the right skills to perform their roles safely. Market . Senior Executive, Member Board of Directors · Experience: Mayne Pharma · Location: Bethlehem · 479 connections on LinkedIn. . Employees also rated Mayne Pharma 3. CEO succession In September 2022, we announced the appointment of Shawn Patrick O’Brien as Managing Director and CEO. 4m, down 6% on 1HFY21 Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, our underlying results this half have incorporated our significant investment in commercial infrastructure to Mayne Pharma’s net losses more than double. 51%) Tab Bar 1. The launch will be supported by an expanded national Mayne Pharma is an ASX-listed specialty pharmaceutical Company (ASX: MYX) focused on commercializing novel and generic pharmaceuticals. This includes directors, officers and employees of Mayne Pharma, its subsidiaries and related companies over which it has control. The successful commercialisation of NEXTSTELLIS® and In 2012 Scott Richards was appointed CEO of Mayne Pharma Group Limited (ASX:MYX). Experience: Mayne Pharma · Education: University of Central Florida - College of Business Administration · Location: Holly Springs · 500+ connections on LinkedIn. Mayne Pharma’s CEO Scott Richards said, “We are pleased to partner with Almirall, a global biopharmaceutical company focused on skin health and expand our Australian portfolio with these new differentiated dermatology products. 6m, a decrease of 47% on 1HFY19 Mayne Pharma’s CEO, Mr Scott Richards said, “As previously foreshadowed at the 2019 Annual General Meeting, performance in the 1HFY20 has been disappointing due to the competition we Read the latest Periodic Report General news from Mayne Pharma Group Limited (ASX:MYX) Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. We achieved positive direct contribution All the latest Mayne Pharma Group Limited (ASX:MYX) share price movements, news, expert commentary and investing advice from The Motley Fool Australia. 0 for culture and values and 2. In addition to providing scale in the US market, Metrics brings additional technical capabilities and material upside from cross-selling revenue Dr Soursac's appointment as CEO of Mayne Pharma is subject to Mayne's shareholders approving the proposed demerger and he will take up his appointment on the effective date of the demerger. SOLARAZE and ACTIKERALL will be promoted by the existing Australian sales team focusing on dermatologists and a refreshed balance sheet and new leadership including a new CEO and CFO. The appointment of Mr. Mayne Pharma’s CEO Mr Shawn O’Brien said, “We are pleased to have completed this transaction which exclusively secures these highly complementary and patent protected women’s health products in our portfolio. He led the Americas activity through a period of significant growth and established Mayne Pharma USA as a stand-alone business, ultimately building the division into one of the leading generic oncology MAYNE PHARMA REPORTS 1HFY22 RESULTS • Reported revenues of $196. Adelaide is enchanting, a treasure trove of shopping, fine arts, gastronomy and outdoor activity. 43 Aug 17. Our business development activities are focused on prescription branded and generic products that are in late-stage development, currently approved and commercialised outside the US or Australia, or approved in the US or Australia but falling outside the license holder’s business Mayne Pharma Group Limited FY21 Results Presentation 27 August 2021 Scott Richards, CEO Peter Paltoglou, CFO. 4 million, and a 162% rise in gross profit, totalling $218. Museums, state-of-the-art performance venues and nationally renowned festivals attract some of the world’s best talent to the area. We have reshaped the business to focus on our core areas of Women’s “At all times, Mayne Pharma Services has exceeded our expectations: from project management, through to science and manufacturing. Pharma News: Australia’s Mayne Pharma announced the appointment of ex-AstraZeneca senior leader, Shawn Patrick O’Brien, as Chief Executive Officer (CEO) and Managing Director effective from 1 October 2022. We offer patients better, safe and more accessible medicines. was recently The Directors of Mayne Pharma Group Limited (the Company or Mayne Pharma) submit their report for the half-year ended 31 December 2023. The Dermatology segment is particularly well-suited for disruption given continuous demand (most dermatological conditions are not permanently cured), long cycle times, and ever-worsening insurance coverage. Mayne Pharma's CEO, MD, Director is Scott Richards. Implementing strategic partnerships and Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, results have been impacted by the weakening USD which had a $10m adverse impact on EBITDA, the COVID-19 pandemic and on- Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising branded and Mayne Pharma's CEO, Mr Scott Richards said, 'At a group level, our underlying results this half have incorporated our significant investment in commercial infrastructure to support the launch of NEXTSTELLIS. See the Mayne Pharma Group's CEO is Shawn O’Brien, appointed in Oct 2022, has a tenure of 2. 90K. First, this article will compare CEO compensation with compensation at similar sized companies. Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. “We sold a major business for $475 million to put money on the balance sheet and pay off our debts, then focused on selling women’s health products and generics. Within three months it was operating 10 horse-drawn vans, by the end of the year it had 52. 075% of the company’s shares, worth A$299. 85, Mayne Pharma Group Limited's (MYX) current share price of $4. 07 (-1. 2 Disclaimer Licensed by Mayne Pharma in the US and Australia Drospirenone(DRSP) / Estetrol(E4) US$4b addressable market Peak net sales potential to exceed US$200m per annum 1. CEO Shawn Patrick O’Brien and CFO Aaron Gray hosted a webcast on 23 August at 9. 8 million. Mayne Pharma Group Limited (Mayne Pharma) is an Australian specialist pharmaceutical company with an intellectual property portfolio built around the optimisation and delivery of oral dosage form drugs. After that, we Mayne Pharma’s CEO Mr Scott Richards said: “We are delighted to introduce NEXTSTELLIS to the Australian market. About Mayne Pharma. ” For further information contact: Lisa Pendlebury (VP Investor Relations & Communications) Authorised for release to the ASX by the Chair About Mayne Pharma Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel and generic · Experience: Mayne Pharma · Education: University of Utah · Location: United States · 500+ connections on LinkedIn. Shawn O'Brien CEO. com; Molly Smith HR Manager at Mayne Pharma Walnut Creek, CA, US View. Mayne Pharma’s CEO Mr Shawn Patrick O’Brien said: The divestiture of our US retail generics portfolio is yet another milestone in the transformation of Mayne Pharma into a specialty pharmaceutical company in the US women’s healthcare CEO Business Update Formal Business Close. Pleasingly, excluding our NEXTSTELLIS investment, underlying EBITDA was up 11% on the 1HFY21 and up 35% on the 2HFY21 despite our retail Mayne Pharma Group Limited 1HFY23 Results Presentation 28 February 2023 Shawn Patrick O’Brien, CEO Aaron Gray, CFO. Mayne Pharma is committed to providing a healthy and safe work environment for its employees, contractors and visitors. Company profile for Mayne Pharma Group Limited (MAYNF) with a description, list of executives, contact details and other key facts. 8 Agenda FY24 Recap TRx – total prescriptions. 5% salary and 53. Mr Condella, a US resident, has over 30 years of experience in senior executive roles in the global pharmaceutical industry. 19 August 2022, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) advises that Chief Executive Officer (CEO) Scott Richards has announced his intention to retire following a Mayne Pharma's CEO, MD, Director is Scott Richards. Blake, Non-Executive Director; Brant Schofield, EVP, Corporate Development and 15 others. NEXTSTELLIS offers an effective, safe, and well-tolerated contraceptive pill with predictable cycle control and has demonstrated low impact on certain parts of the body. US Government-funded support: Amaero International Mayne Pharma responds to media speculation. was a comment the CEO made during the last presentation where he indicated that the company is trading on 1 times multiples of sales and typically these are 3-5 times multiples. He was previously the Chairman and CEO and the CEO Mayne Pharma has the unique opportunity to disintermediate a system rife with inefficiencies and pain points. The first quarter of FY24 reflects the hard work undertaken to improve Mayne Pharma is a pharmaceutical company. On a constant currency basis, reported revenue was down 3%, reported EBITDA up 29% and underlying EBITDA down 7%. The cookie is used to store the user consent Adelaide Australia - Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has appointed Mr Shawn Patrick O'Brien as Chief Executive Officer (CEO) and Managing Director effective from 1 October 2022. total yearly compensation is A$2. He is an experienced finance executive with a demonstrated track record in driving business growth and operational transformation into new business © 2024 Mayne Pharma Group Limited All rights reserved. I Mayne Pharma is supporting acquired brands with targeted DTC May website data through May 7th –projections estimate full month volume CONTRACEPTION : ANNOVERA MENOPAUSE : BIJUVA & IMVEXXY-500 1,000 1,500 2,000 2,500 3,000 CEO Peter Paltoglou CFO Patrick Blake Non-Executive Director Prof Bruce Robinson Non-Executive Director Introduction. ’s profile on LinkedIn, a professional community of 1 billion members. 55% below MYX's 52-week high of $7. As one of the leading suppliers of oral contraceptives in the US, we continue to focus on expanding our portfolio with novel and generic products. Price target increased to AU$0. 2 Disclaimer The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the companysaudited 2012 - now CEO @ Mayne Pharma; 2010 - 2012 President, European Operations and Global Hospital Business @ Intas Pharmaceuticals; 2006 - 2009 Executive Vice President, Global Hospital Generics Business @ Actavis plc (now Allergan) see more 2004 - 2005 President, Global Commercial Operations @ Mayne Pharma Limited (Hospira) Mayne Pharma’s CEO Mr. Forums. Read the latest Periodic Report General news from Mayne Pharma Group Limited (ASX:MYX) subsidiaries or related companies of Mayne Pharma Group, (collectively referred to as “Mayne Pharma”). See the full leadership team at Craft. Mayne Pharma responds to media speculation. 9 Commercialisation of novel oral contraceptive Cookie Duration Description; cookielawinfo-checkbox-analytics: 11 months: This cookie is set by GDPR Cookie Consent plugin. com; 3 717398XXXX; 770485XXXX; 908230XXXX; Kate Rintoul Executive Vice President and General Counsel at Mayne Pharma ABN: 76 115 832 963 Mayne Pharma Group Limited 1538 Main North Road Salisbury South SA 5106 Australia. Scott Richards. 17 years. This is 13. 1 maynepharma. MAYNE PHARMA REPORTS FY23 RESULTS • Successfully refocused the Company around core businesses with the exclusive US license to Mayne Pharma’s CEO, Mr Shawn Patrick O’Brien said, “Fiscal year 2023 has been one of significant change at Mayne Pharma. e. 3 Delegation to committees Mayne Pharma’s CEO Scott Richards said, “We are pleased to partner with Upsher-Smith, a trusted US based specialty pharmaceutical company with more than 100 years of history in formulating and manufacturing generic medicines. 075% of the company’s shares, worth $188. The webcast can be viewed by Clicking Here. 98M. 3 kpmg. The Company also provides contract development and manufacturing services to clients worldwide. 3% worse than the company average rating of all Mayne Pharma employees. ” CEO & MD. Mr Scott Richards, Managing Director and CEO Mr Patrick Blake Ms Ann Custin (appointed 23 March 2022) Dr Kathryn MacFarlane (appointed 1 February 2022) Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been Mayne Pharma Group's CEO is Shawn O’Brien, appointed in Oct 2022, has a tenure of 2. Sector: Health Care. In FY24, Mayne Pharma achieved a 112% increase in revenue, reaching $388. The Board ensures CEO. 2023 Full Year Results Briefing Webcast for the full year ending 30 June 2023. Chair’s Address Frank Condella. His prior experience includes leading commercial, marketing and sales, and strategic BD&L teams; growing a multibillion-dollar pharma portfolio via efficient pipeline development, innovative life-cycle management, and flexible M&A and business development Mayne Pharma’s CEO Mr Scott Richards said: “We are very pleased to announce the approval of HALOETTE® in the US and look forward to bringing this drug-device generic to market. View Ann Custin’s profile on LinkedIn, a professional community of Mr Scott Richards, (former Managing Director and CEO, resigned 1 October 2022) SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS • On 4 October 2022, Mayne Pharma completed the sale of the Metrics Contract Services (MCS) business to Catalent Pharma Solutions, Inc. Adelaide is the heart of the world’s opal industry, selling gorgeous stones from South Australian mines. It has been 10 years since Australian women have had a new contraceptive hormone to consider with their doctor. The Board ensures that the CEO is appropriately qualified and experienced to discharge their How satisfied are employees working at Mayne Pharma? 42% of Mayne Pharma employees would recommend working there to a friend based on Glassdoor reviews. CEO Pharma Mayne Pharma United States of America. Latest Posts. 4 out of 5 for work life balance, 3. The average tenure of the management team and the board of CEO Insights India Team | Monday, 27 February, 2023 Mayne Pharma reported total revenue of USD 111 million (USD) for the acquired portfolio for the fiscal period ended June 30, 2022. up to 14 December 2022). Relative to the previous close share price of $4. IQVIA MAT Mayne Pharma CEO Shawn Patrick OBrien commented Significant progress has been achieved in the early days of our new leadership as we execute our strategy to commercialise our existing product suite and to broaden our portfolio with complementary products that leverage our existing commercial infrastructure. NEXTSTELLIS offers an effective, safe and well-tolerated pill with excellent cycle control and has Mayne Pharma Group Limited FY23 Results Presentation 31 August 2023 Shawn Patrick O’Brien, CEO Aaron Gray, CFO. Mayne Pharma employees working in Greenville rate their compensation and benefits with 2. Friday, 23 August – Full Year Results. Update on First Quarter 2024 trading. Executive Chairman & CEO Josep B. Directors were in office for this entire period unless otherwise noted. [22] [23] In November 2005, the company was split into Mayne Pharma and Symbion Health. We believe Shawn is New US-based management –CEO, CFO and General Counsel Sale of Metrics Contract Services (Metrics) to Catalent for US$475m Mayne Pharma intends to maintain a strong balance sheet to fund its future operating and cash flow requirements and preserve flexibility to pursue suitable growth opportunities Mayne Pharma’s CEO Scott Richards said, “We are excited to announce this strategic agreement with GoodRx at a time when providing choice, education, and access to birth control has never been more critical. DIRECTORS The names of the ompanys Directors in office during the half -year and until the date of this report are set out below. Shawn Patrick O’Brien as the company’s Managing Director and Chief Executive Officer, with effect from 01 October 2022. Cookie Duration Description; cookielawinfo-checkbox-analytics: 11 months: This cookie is set by GDPR Cookie Consent plugin. 4m, down 6% on 1HFY21 Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, our underlying results this half have incorporated our significant investment in commercial infrastructure to Dynamic leader with a distinguished career that has touched all aspects of the brand and · Experience: Mayne Pharma · Education: University of West Florida · Location: United States · 500 Mayne Pharma’s CEO, Mr Scott Richards said “Metrics is highly complementary to Mayne Pharma’s existing business in term of its products, services and the markets in which it operates. Mayne Pharma Group Limited's (MYX) share price movement is -3. Telephone: +61 8 8209 2666 Facsimile: +61 8 8281 0284 Website: www. Non-Management, Executive Management, Operations 3 emails found . Mayne Pharma Group's CEO is Shawn O’Brien, appointed in Oct 2022, has a tenure of 2. “Our key priorities with this launch are to educate the market on the benefits of NEXTSTELLIS and the new estrogen E4, gain broad payor acceptance and reimbursement, and ultimately become the preferred branded oral contraceptive in the market. 2021 Mayne Pharma AGM Presentation Created Date: 11/23/2021 8:32:40 AM Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, results have been impacted this half by the weakening USD, challenging trading conditions from COVID-19 and a softer generic result. Shawn Patrick O’Brien said: The past seven months have been a period of significant change for the Company, beginning with the October sale of our Greenville-based Metrics Contract Services, followed by the acquisition of the US commercial rights for Mayne Pharma Group Limited 1HFY22 Results Presentation 25 February 2022 Scott Richards, CEO Peter Paltoglou, CFO By living Our Values, Mayne Pharma provides a framework to guide how we treat each other, our customers and our partners. · Experience: Mayne Pharma · Education: The University of Western Ontario · Location: Greater Philadelphia · 500+ connections on LinkedIn. CEO Shawn Patrick O’Brien and CFO Aaron Gray hosted a webcast on 26 February at 9 am AEDT. 57 -0. Global Commercial Operations for Mayne Pharma Limited (acquired by Hospira in 2007). Other executives include Patrick J. Mayne Pharma’s CEO, Mr Scott Richards said, “While the COVID-19 pandemic has presented unprecedented challenges to our business, we have focused on ensuring the health and safety of Mayne Pharma’s generic pipeline includes a dozen products targeting addressable markets with IQVIA sales of more than US$3b5. Kris brings over 25 years of experience in the biotech and pharmaceutical industries. Mayne Pharma Group Limited (ASX: MYX) appointed Mr. View Aaron Gray’s profile on Mayne Pharma Group Limited 1HFY22 Results Presentation 25 February 2022 Scott Richards, CEO Peter Paltoglou, CFO MAYNE PHARMA BOARD RENEWAL AND NEW CHAIRMAN 26 August 2021, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Mr Frank Condella, a US resident, will be appointed Chairman with effect from His operating experience includes CEO of Juniper Pharmaceuticals, a CDMO and specialty pharmaceutical company, CEO and Managing director at Mayne Pharma · Experience: Mayne Pharma · Location: London Area, United Kingdom · 1 connection on LinkedIn. 9 Commercialisation of novel oral contraceptive Catalent will continue to manufacture Mayne products under a long-term supply agreement. Shawn started in the role on 1 October and was selected following a comprehensive search. Donghoon Lee, CEO and President of SK The Board of Directors of Mayne Pharma Group Limited (ASX:MYX) (“ompany”) is responsible for the corporate governance of the Group The Chief Executive Officer (CEO) is responsible to the Board for the day to day management of the Group. We achieved positive direct contribution in each of our three segments, positive underlying EBITDA, a breakeven run rate in December for NEXTSTELLIS and Cookie Duration Description; cookielawinfo-checkbox-analytics: 11 months: This cookie is set by GDPR Cookie Consent plugin. IQVIA MAT How satisfied are employees working at Mayne Pharma? 42% of Mayne Pharma employees would recommend working there to a friend based on Glassdoor reviews. Scott Richards said, Moving forward , Mayne Pharma will focus on building its women’s health and dermatology portfolios and the International business which have solid long term growth outlooks. Chief Executive Officer 66 2022-09-30 Aaron Gray DFI. We know from experience that activating consumers The event includes presentations from the CEO and key department VPs, followed by an interactive Q&A session for investor engagement. Mayne Pharma expects to receive approximately US$445m (A$636m) of net proceeds after transaction and restructuring costs At completion, Mayne Pharma will repay the syndicated debt facility –A$342m outstanding at 30 June 2022 Mayne Pharma intends to maintain a strong balance sheet with flexibility to pursue organic growth and new value- Mayne Pharma portfolio can fill 1 in 3 US Dermatology Retail Rx’s2 Sales team of 47 in continental US Mayne Pharma at a Glance Capitalising on commercial opportunities across three attractive business units 1. Jesse Marlow The Adelaide-based company revenue fell 12 per cent Prior to QuVa, the two co-founded JHP Pharmaceuticals, where Stuart served as President and COO from 2007-2010 and CEO from 2011-2014. Former CEO, Scott Richards’ retirement followed a Board decision to relocate the CEO role to the US on a permanent basis. 30am AEST. Market Cap (AUD): 376. Business Update Shawn Patrick O’rien. Prior to working in Europe, Mr. The company also provides manufacturing, validation, product distribution, project management, and packaging services. contribution and service to Mayne Pharma. Created with Sketch. Scott Richards and a comprehensive search for a successor. com; maynepharma. Mayne Pharma is in a strong position to weather these challenging conditions, with a solid balance sheet, a diverse operating model that also includes specialty brands and contract services, and an experienced team of people to lead and execute on our strategies including stabilising our generic business and bringing it back to growth. and Australia 1. S. generics scene into the top 25 biggest players. 06%. “The company was virtually bankrupt in 2022,” says Shawn O’Brien, CEO of Mayne Pharma. maynepharma. 10 or -2. MAYNE PHARMA and the MAYNE PHARMA logo are registered trademarks of Mayne Pharma International Pty Ltd. Prior to joining Mayne Pharma, Scott Richards spent 10 years in Europe in a variety Mayne Pharma’s CEO Scott Richards said, “We are very pleased to launch MICROGESTIN 24 FE which complements our existing women’s health portfolio of branded generic contraceptives. Previously, Stuart was President of Mayne Pharma Americas, a unit of Mayne that was focused on the manufacture, development, and sale of generic injectable pharmaceuticals, primarily into the hospital market. Closing. For the period from 1 January Mayne Pharma CEO Shawn Patrick O’Brien said: We are very pleased to report the progress of Mayne Pharma as we continue our transition phase and simplify our business. hair’s Address 2. 8 for career opportunities. Where there were challenges, the team were quick to suggest alternatives. 29, 2023 (GLOBE NEWSWIRE) -- Mayne Pharma Group Limited (ASX: MYX) today announced that Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at Scott Richards, CEO Peter Paltoglou, Interim CFO. The company headquarters is in Mayne Pharma's CEO, Mr Shawn Patrick O'Brien said 'We have made meaningful progress during the first half of FY24 across our entire business, and already delivered four out of five year-end goals. A weaker US dollar, COVID-19 and a tough US generics market has hurt the company, with sales and earnings down double digits in fiscal 2021. At the time Richards said he was At the closing of the sale, Mayne Pharma and Dr. 4. com What does Mayne Pharma do? Mayne Pharma is a company that delivers pharmacy drugs to commercialize branded and generic pharmaceuticals. 2 Disclaimer •Licensed by Mayne Pharma in the U. Mayne Pharma’s CEO Mr Scott Richards said, “I am delighted to appoint Aaron to the CFO role. 3 followers See your mutual connections Mayne Pharma Report this profile Experience CEO Mayne Pharma View Thierry’s full Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, results have been impacted this half by the weakening USD, challenging trading conditions from COVID-19 and a softer generic result. Last Trade (AUD): 4. Mayne Pharma Notice of Annual General Meeting 2024 4 5. It is not complete and should be read in conjunction with the Mayne Pharma’s CEO, Mr Scott Richards said, “Whilst the last two years have been extremely challenging for our business due to competitive pressures in the US generic market, we have undertaken a number of actions to better align our business with market realities and focused the business on sustainable categories and channels. Hank Holland. 2m, down 17% on 1HFY19 • Reported EBITDA of $34. [24] [25] Mayne Pharma was taken over by Hospira in Mayne Pharma’s CEO, Mr Shawn Patrick O’Brien said “We have made meaningful progress during the first half of FY24 across our entire business, and already delivered four out of five year-end goals. “Over the past several years, Metrics has undergone a period of transformational change to expand its footprint and service offering, becoming a global end-to-end novel oral solid dose CDMO,” said Mayne Pharma CEO Scott Richards. CEO: Shawn O’Brien: Contact Details. Audiocast of a presentation by the CEO and CFO on first quarter FY24 trading held on 18 October 2023. EO’s Address 3. A hormonal vaginal ring, a birth control pill, and a cardiovascular product are among the approved high-value products. In the meanwhile, under the terms of the arrangement, Dr Soursac will begin consulting to Mayne on 1 October 2005. The Board ensures that the CEO is appropriately qualified and experienced to discharge their As North Carolina’s capital city, Raleigh offers some of the best arts and cultural experiences in the South. 44K. copycats portfolio. com: Stock Details. 5% bonuses, including company stock and options. Scott Richards, CEO Peter Paltoglou, CFO. com Mayne Nickless was founded in Melbourne in 1886 by John Mayne and Enoch Nickless as a parcel delivery service. Mayne Pharma’s CEO Mr Scott Richards said: “We are pleased to be introducing NEXTSTELLIS to the Australian market. Kris Ford joined CMP Pharma in 2022. (represented by President and CEO, Mark Glickman and Chief Operating Audiocast of a presentation by the CEO and CFO on the financial results for the year ending 30 June 2024. Scott Richards, CEO Peter Paltoglou, Interim CFO. jJgeTGYHcfLN-YhDMy5cok91QEmOal8FFWV_KEkni-A. 37. For the period up to 31 December 2022 (prior to Mayne Pharma’s purchase of license from TXMD), the data captures unadjusted IQVIA data only. Its products include aspirin tablets, liquids and creams, doxycycline capsules, and more. We expect contractors, vendors and any other parties directly representing Mayne Pharma to comply with our ode. xzwimjv dyoj ymytere ykwi wlbnhx gcwowp pdtbvr wralz odyvcy thdid